Date Filed | Type | Description |
10/04/2023 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on PaxMedica, Inc.
Txns:
| Paid exercise price by delivering 6,536 shares
@ $0.2861, valued at
$1.9k
|
|
05/30/2023 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
05/04/2023 |
3
| CASAMENTO CHARLES J (Director) has filed a Form 3 on GT Biopharma, Inc. |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/02/2023 |
5
| CASAMENTO CHARLES J (Director) has filed a Form 5 on RELMADA THERAPEUTICS, INC. |
01/05/2023 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Granted 84,745 shares
@ $0 |
|
12/20/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/04/2022 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on PaxMedica, Inc.
Txns:
| Granted 51,583 shares
@ $0 |
|
10/04/2022 |
3
| CASAMENTO CHARLES J (Director) has filed a Form 3 on PaxMedica, Inc. |
05/26/2022 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Granted 91,235 options to buy
@ $19.03, valued at
$1.7M
|
|
04/05/2022 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Sold 3,300 shares
@ $29, valued at
$95.7k
Exercised 19,800 options to buy
@ $3.24, valued at
$64.2k
|
|
02/28/2022 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on Eton Pharmaceuticals, Inc.
Txns:
| Granted 50,000 options to buy
@ $3.78, valued at
$189k
|
|
01/03/2022 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on First Wave BioPharma, Inc.
Txns:
| Granted 34,482 options to buy
@ $1.45, valued at
$50k
|
|
09/24/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/19/2021 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Exercised 10,000 options to buy
@ $4.6, valued at
$46k
|
|
07/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/22/2021 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
06/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/05/2021 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Sold 1,309 shares
@ $35.9265, valued at
$47k
Sold 1,691 shares
@ $35.0403, valued at
$59.3k
|
|
03/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/16/2021 |
5
| CASAMENTO CHARLES J (Director) has filed a Form 5 on Eton Pharmaceuticals, Inc. |
02/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/06/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/02/2020 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Gifted 21,223 shares
@ $0 Sold 3,000 shares
@ $35.7397, valued at
$107.2k
|
|
11/03/2020 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Sold 3,000 shares
@ $30.2879, valued at
$90.9k
|
|
10/02/2020 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Sold 3,000 shares
@ $37.9852, valued at
$114k
|
|
09/02/2020 |
4
| CASAMENTO CHARLES J (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.
Txns:
| Sold 3,000 shares
@ $34.7356, valued at
$104.2k
|
|
08/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/04/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/02/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|